Active, not recruitingPhase 3NCT06274801
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Studying Pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- GB002, Inc.
- Principal Investigator
- Richard Aranda, MDGossamer Bio Inc.
- Intervention
- Seralutinib(drug)
- Enrollment
- 316 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2024 – 2026
Study locations (30)
- Valley Advanced Lung Diseases Institute, Fresno, California, United States
- Department of Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, United States
- UC Davis Health Medical Center, Sacramento, California, United States
- Stanford Healthcare, Stanford, California, United States
- University of Florida Health, Gainesville, Florida, United States
- Mayo Clinic Jacksonville, Jacksonville, Florida, United States
- Piedmont Physicians Pulmonary & Sleep Medicine of Buckhead, Atlanta, Georgia, United States
- The Emory Clinic, Atlanta, Georgia, United States
- Northside Hospital - Atlanta, Atlanta, Georgia, United States
- UI Health Hospital, Chicago, Illinois, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Norton Pulmonary Specialists, Louisville, Kentucky, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- University of Nebraska Medical Center, Omaha, Nebraska, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06274801 on ClinicalTrials.govOther trials for Pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07593027A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
- RECRUITINGNANCT07563322Mechanistic Study of Nicotinamide Riboside on NAD+ Biology in Individuals With Combined Pulmonary HypertensionVanderbilt University Medical Center
- ACTIVE NOT RECRUITINGNANCT07391228Cognitive Alterations in Pulmonary Arterial Hypertension (PAH)Alessandra Gorini
- RECRUITINGNANCT06871293Evaluating the Impact of a Functional and Cognitive Strategy in Patients With Long Covid-19Fundación Cardioinfantil Instituto de Cardiología
- RECRUITINGNANCT06911632Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary HypertensionTempus AI
- RECRUITINGPHASE2NCT05937854Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PHVA Office of Research and Development
- RECRUITINGNCT06291389Intraoperative Peak Airway Pressure Changes on Postoperative Pulmonary Function After Muscle PlicationAl-Azhar University
- ACTIVE NOT RECRUITINGNANCT07253363Circulating Activin-A and FSTL3 in Precapillary Pulmonary HypertensionAssistance Publique - Hôpitaux de Paris